|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||1.0500 - 1.0500|
|52 Week Range||0.5100 - 1.9300|
|Beta (5Y Monthly)||1.29|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Nuvo Pharmaceuticals Inc. (TSX: NRI) (OTCQX: NRIFF) d/b/a Miravo Healthcare ("Miravo" or the "Company"), a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, today announced that its wholly owned subsidiary, Nuvo Pharmaceuticals (Ireland) DAC trading as Miravo Healthcare ("Miravo Ireland"), has entered into an exclusive license and supply agreement (the "License Agreement") with SK Chemicals Co., Ltd. ("SK Chemicals") for the exclusive right
Nuvo Pharmaceuticals Inc. (TSX: MRV) (OTCQX: MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced it expects to release its second quarter 2021 financial results before markets open on Monday, August 9, 2021.
RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving - an investor conference themed around investor education and advocacy begins next week, July 13th \- 15th, 2021. More than 50 companies are scheduled to conduct virtual presentations over the three-day period as well as 1x1 meetings with qualified investors throughout the event.